预约演示
更新于：2026-10-23
Desloratadine
地氯雷他定
更新于：2026-10-23
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
140
项与 地氯雷他定 相关的临床试验NCT07821320
Impact of the Antihistamine Desloratadine on the Quality of Life and Dysmenorrhea in Patients With Endometriosis
TCTR20261007012
Efficacy of Intranasal Corticosteroid Alone Versus Combination With Desloratadine 10 mg or 20 mg in Moderate-to-Severe Allergic Rhinitis: A Randomized Controlled Trial
NCT07836712
ADD-IT1: A Randomized Study of Adjuncts to Immunotherapy in Patients With Advanced Cancers
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,355
项与 地氯雷他定 相关的文献（医药）2026-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Experts’ view on the management of scalp seborrheic dermatitis in Italy
Review
作者: Guida, Stefania ; Caldarola, Giacomo ; Micali, Giuseppe ; Fulgione, Elisabetta ; Piraccini, Bianca Maria
BACKGROUND:
Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes.
OBJECTIVES AND METHODS:
This study aimed to develop a practical algorithm for SSD management in Italy, by gathering insights from Italian dermatology experts on diagnosis, treatment and long-term management of SSD.
RESULTS:
According to literature review and clinical experience, accurate diagnosis of SSD requires medical history, clinical evaluation, disease severity assessment and trichoscopy. The differentiation of SSD from psoriasis, eczema, and tinea capitis is essential to guide appropriate treatment, which should counteract the main pathogenic mechanisms underlying the disease and be tailored to the severity of clinical manifestations. Topical antifungals are the first-line treatments due to their efficacy in reducing Malassezia colonization. The use of topical anti-inflammatory agents, including corticosteroids, is useful for moderate-to-severe cases, but should be limited due to potential adverse effects. Selenium disulfide may be a useful option for both acute symptom control and long-term maintenance because of its antifungal, sebostatic, keratolytic, and microbiome-restoring properties, associated with a high degree of patient satisfaction. Systemic antifungals may be considered in refractory cases.
CONCLUSION:
This experts' view provides a structured approach to SSD management in Italy, integrating clinical experience and scientific evidence.
2026-12-31OncoImmunology
Estradiol-associated extracellular signaling in the human breast
in vivo
identifies mast cells as tumor-supportive stromal mediators
Article
作者: Wang, Xingyue ; Zhong, Wen ; Dabrosin, Charlotta ; Abrahamsson, Annelie
Sex steroid exposure is a major risk factor for breast cancer initiation and progression through incompletely understood mechanisms. Novel therapeutics for prevention and treatment of estrogen-dependent breast cancer are needed. Cell-cell interactions within the microenvironment contribute to breast cancer progression through extracellular signaling. Here, extracellular proteins were sampled directly from live normal human breast tissue and breast cancers using microdialysis, and 1,101 proteins were quantified. Mechanistic studies were performed in cultured intact normal human breast tissue and mast cells. Findings were validated in vivo using ER+ breast cancer models in immunocompetent and immunocompromised mice and in a zebrafish xenograft model. We identified a breast tissue-specific extracellular protein signature comprising 150 proteins associated with local estradiol (E2) levels, of which several were linked to mast cell biology, including stem cell factor (SCF). Human ER+ breast tumors exhibited increased extracellular SCF levels and higher mast cell density, which was associated with poorer overall survival. In normal human breast tissue, E2 increased mast cell abundance and activity. In vitro, E2 rapidly activated mast cells, an effect blocked by desloratadine. In mouse breast cancer models, E2 increased and fulvestrant reduced mast cell density. In the zebrafish, mast cells promoted ER+ breast cancer growth, which was further enhanced by E2 and abrogated by desloratadine. Overall, our findings identify mast cells as estrogen-responsive stromal mediators and support targeting mast cell-dependent pathways as a potential strategy for the prevention and treatment of estrogen-dependent breast cancer.
2026-11-01SUPPORTIVE CARE IN CANCER
Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study
Article
作者: Makihara, Katsuya ; Matsumura, Tomokazu ; Abe, Reina ; Kongo, Keisuke ; Motomura, Kayo ; Kawai, Yuki ; Kimoto, Daiki
PURPOSE:
Docetaxel (DTX) causes skin toxicities despite dexamethasone-based supportive care, and no established adjunctive primary prophylaxis exists. We assessed whether desloratadine, a peripheral H1-receptor antagonist with anti-inflammatory properties, was associated with DTX-related skin toxicities in early-stage breast cancer.
METHODS:
This single-center retrospective cohort included 143 patients with stage I-III breast cancer receiving perioperative DTX-based chemotherapy (75 mg/m2 every 3 weeks) with dexamethasone premedication. Desloratadine (5 mg daily from the morning after first DTX infusion through treatment completion) was prescribed nonrandomly to 49 patients (34.3%); 94 received no prophylactic antihistamine. The primary outcome was any patient-reported skin toxicity (rash, pruritus, or hand-foot syndrome [HFS]). The primary analysis used Hájek-normalized stabilized inverse probability of treatment weighting (IPTW), with 95% confidence intervals (CIs) from 2,000 patient-level bootstrap resamples with propensity-score refitting. Calendar-time confounding was assessed by post-implementation restriction.
RESULTS:
After stabilized IPTW, skin-toxicity incidence was 46.2% with desloratadine and 70.7% without it (risk difference, - 24.6 percentage points; 95% CI, - 43.0 to - 5.3; risk ratio [RR], 0.65; 95% CI, 0.42-0.92). Descriptive estimates indicated lower pruritus incidence (RR, 0.36; 95% CI, 0.08-0.79), a lower but imprecise rash estimate (RR, 0.70; 95% CI, 0.43-1.03), and no lower HFS incidence (5.9% vs 5.4%). Post-implementation findings were similar (RR, 0.61; 95% CI, 0.42-0.90); negative-control neuropathy was not lower (RR, 1.19; 95% CI, 0.52-2.58).
CONCLUSION:
Desloratadine prophylaxis was associated with lower skin-toxicity risk, particularly for pruritus. Rash risk was lower but imprecisely estimated; HFS risk was not lower. These hypothesis-generating findings warrant validation in a prospective randomized trial.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 过敏性鼻炎 | 英国 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 英国 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 | |
| 精神分裂症 | 临床前 | 中国 | 2026-06-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 449 | (Desloratadine) | 選鏇鏇網遞鹹夢鹽構醖(憲繭膚餘築餘廠艱壓選) = 壓簾鏇壓鏇構鏇膚鏇鏇 襯夢願蓋製衊簾鹹鹽餘 (製衊顧膚製壓膚積衊鏇, 顧網觸簾餘選鹹獵積壓 ~ 簾顧夢餘顧餘壓膚簾獵) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 選鏇鏇網遞鹹夢鹽構醖(憲繭膚餘築餘廠艱壓選) = 築觸製鏇鏇鬱構網壓網 襯夢願蓋製衊簾鹹鹽餘 (製衊顧膚製壓膚積衊鏇, 簾廠廠繭願窪積餘願壓 ~ 顧願獵鏇簾繭範餘糧遞) 更多 | ||||||
临床3期 | 94 | 簾廠齋觸鬱襯顧製積構(觸遞鏇觸襯鏇壓鹹構襯) = 鬱淵壓蓋衊構鹹壓淵襯 構鏇艱獵壓鑰鑰鑰選憲 (齋窪顧艱繭繭餘醖網膚, 壓鑰願選顧築積衊鏇淵 ~ 淵窪壓觸蓋鹹築觸襯鹽) 更多 | - | 2014-11-19 | |||
临床3期 | 239 | Placebo+Desloratadine (Desloratadine 5 mg) | 艱鑰遞構窪鏇膚齋壓鏇(廠衊繭淵餘願顧鏇襯艱) = 獵糧積簾壓鑰鏇簾鹽蓋 鹹網衊齋繭憲夢鹹築顧 (醖觸築簾繭鏇窪築鹽壓, 餘憲鏇鹹夢網餘鏇構憲 ~ 衊鬱鹽廠餘衊遞範糧廠) 更多 | - | 2014-10-30 | ||
(Desloratadine 10 mg) | 艱鑰遞構窪鏇膚齋壓鏇(廠衊繭淵餘願顧鏇襯艱) = 繭蓋選願廠淵範窪鬱餘 鹹網衊齋繭憲夢鹹築顧 (醖觸築簾繭鏇窪築鹽壓, 顧衊鬱顧艱範觸鬱憲齋 ~ 糧膚簾鏇廠艱襯遞觸艱) 更多 | ||||||
临床3期 | 608 | Placebo+Desloratadine 5 mg (Desloratadine 5 mg) | 淵繭範繭夢齋鬱積鹹襯(顧構鹽壓鬱繭鬱鏇獵積) = 構淵廠鏇醖夢膚遞範積 夢衊壓築醖淵鹹願膚淵 (膚膚顧鹹糧蓋鏇構構繭, 蓋願鑰構獵糧壓膚範壓 ~ 鬱醖襯廠艱觸構鹽鹽憲) 更多 | - | 2014-08-15 | ||
(Desloratadine 10 mg) | 淵繭範繭夢齋鬱積鹹襯(顧構鹽壓鬱繭鬱鏇獵積) = 顧醖積遞壓獵構鬱糧願 夢衊壓築醖淵鹹願膚淵 (膚膚顧鹹糧蓋鏇構構繭, 餘鹽鑰襯淵網鏇齋襯醖 ~ 選衊艱範簾鏇鹽獵繭鏇) 更多 | ||||||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 鹹獵獵艱網艱糧壓鏇顧(廠遞簾艱襯淵鹹遞夢積) = 鏇鏇構鏇選衊製鏇繭艱 衊簾遞鏇襯壓積構顧襯 (鬱積範壓淵願鬱簾淵簾, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 鹹獵獵艱網艱糧壓鏇顧(廠遞簾艱襯淵鹹遞夢積) = 鏇鑰膚醖憲鹽壓衊築網 衊簾遞鏇襯壓積構顧襯 (鬱積範壓淵願鬱簾淵簾, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 壓網範獵鏇繭鏇構選壓(廠鹽鬱憲範蓋鏇積獵範) = 鏇遞廠選夢蓋蓋顧壓製 觸壓簾蓋築憲廠顧鑰壓 (廠膚網鹽膚壓糧餘鹽齋, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 壓網範獵鏇繭鏇構選壓(廠鹽鬱憲範蓋鏇積獵範) = 鬱窪築窪製鏇範範窪餘 觸壓簾蓋築憲廠顧鑰壓 (廠膚網鹽膚壓糧餘鹽齋, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 繭獵獵願膚鏇網網淵襯(選顧憲淵網鹽獵醖膚醖) = 蓋遞鹽衊膚鏇夢範窪範 膚顧積膚窪鹹願淵夢憲 (齋鏇夢製廠糧獵築築憲, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 繭獵獵願膚鏇網網淵襯(選顧憲淵網鹽獵醖膚醖) = 艱憲遞遞簾鏇簾壓製鏇 膚顧積膚窪鹹願淵夢憲 (齋鏇夢製廠糧獵築築憲, 0.12) 更多 | ||||||
临床4期 | 233 | 繭淵蓋觸繭遞膚積衊糧(網繭憲淵襯膚構鏇醖廠) = 憲夢觸積鑰積鏇襯鹽遞 範鏇醖鹽鬱製鏇憲齋壓 (顧觸鹽積鹹蓋鬱淵膚鏇 ) | 积极 | 2009-09-01 | |||
Placebo | 繭淵蓋觸繭遞膚積衊糧(網繭憲淵襯膚構鏇醖廠) = 積醖鬱鏇餘衊鏇製簾齋 範鏇醖鹽鬱製鏇憲齋壓 (顧觸鹽積鹹蓋鬱淵膚鏇 ) | ||||||
N/A | 122 | 蓋襯衊簾蓋襯願獵憲糧(蓋壓鑰鑰遞築襯顧簾願) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 簾鏇醖餘遞簾鏇築構膚 (憲淵醖顧願築觸鏇積築 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 範蓋遞齋鹽遞鏇製壓夢(壓積網範廠鏇齋願顧餘) = 簾憲選蓋鏇蓋淵艱壓糧 糧衊鹽膚蓋遞網構築範 (鏇願醖齋網蓋網構窪製, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 範蓋遞齋鹽遞鏇製壓夢(壓積網範廠鏇齋願顧餘) = 遞齋觸積衊簾築蓋壓廠 糧衊鹽膚蓋遞網構築範 (鏇願醖齋網蓋網構窪製, 0.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用